Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 4trametinib 3pembrolizumab 3Specimen Handling 3ulixertinib 2larotrectinib 2binimetinib 2Surveys and Questionnaires 2Radiosurgery 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cisplatin 2Biopsy 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1naporafenib 1lenvatinib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × PLX8394 × Dermatologic × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡